• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 2022

View Archived Issues
DNA, drug development concept art.

Repeat expansions are repeat feature of cancer genomes

Repeat expansions of two or more base pairs cause dozens of neurological disorders – Huntington’s disease, which is caused by an expansion of the triplet CAG in the coding sequence for huntingtin, is perhaps the most famous one. Now, investigators at Stanford University have shown that cancer genomes, too, frequently feature repeat expansions. Read More

Bile acid receptor regulates gut innate immunity

The farnesoid X receptor (FXR), a bile acid receptor, plays a direct role regulating innate immune cells in the gut, and treating mice with an FXR agonist improved symptoms of inflammatory bowel disease (IBD). The findings provide a link between diet and innate immunity, and could lead to better ways to treat IBD. “The intestine is a major target for inflammation and inflammatory disease, particularly in the modern Western culture, where high-fat diets are becoming very prevalent,” Ronald Evans told BioWorld. Read More
Parkinson's disease illustration showing neurons containing alpha-synuclein

SLS-004 increases recovery of TH+ dopaminergic neurons in animal model of Parkinson's disease

Seelos Therapeutics Inc. has announced in vivo data demonstrating that a single dose of SLS-004 downregulated the production of α-synuclein in an established α-synuclein overexpressing animal model of Parkinson's disease. Read More
Red-blood-cell-DNA.png

Protein S-targeting siRNA improves hemostasis potency in hemophilia

SLN-140 (Silence Therapeutics plc) is a novel small interfering RNA (siRNA) targeting protein S for the treatment of hemophilia A (HA). Researchers from the University of Bern recently presented data from studies conducted in animal models of HA, performed to evaluate the safety and efficacy of SLN-140. Read More

Halda Therapeutics discloses new PROTACs for cancer

Halda Therapeutics Opco Inc. has patented proteolysis-targeting chimeric (PROTAC) compounds comprising an E3 ubiquitin ligase cereblon (CRBN)-binding moiety covalently bonded to a protein-targeting moiety via linker reported to be useful for the treatment of cancer and hepatitis. Read More
Microscopic image of acute myeloid leukemia (AML) cells.

Researchers unveil TSC22D3 as a novel prognostic biomarker in AML

TSC22 domain family member 3 (TSC22D3) is a glucocorticoid-induced gene that plays a key regulatory role in immunosuppression and cell proliferation. Its prognostic usefulness in acute myeloid leukemia (AML) has not been deeply investigated yet. Read More
Handshake with DNA, molecules

Genprex enters license agreement with University of Pittsburgh to support diabetes program

Genprex Inc. has entered into a license agreement with the University of Pittsburgh designed to strengthen its diabetes program. The agreement grants Genprex a worldwide, exclusive license to certain patent applications and related technology and a worldwide, nonexclusive license to use certain related know-how, all related to modulating autoimmunity in type 1 diabetes by using gene therapy. Read More

Innocure Therapeutics identifies new PROTACs

Innocure Therapeutics Inc. has divulged piperidinediones as proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase cereblon (CRBN)-binding moiety covalently linked to bromodomain-containing protein 4 (BRD4)- and/or tyrosine-protein phosphatase non-receptor type 11 (PTPN11)-targeting moiety via linker reported to be useful for the treatment of cancer. Read More

Japanese investigators describe new compounds for malaria

Nagasaki University and Shionogi & Co. Ltd. have synthesized quinolone compounds reported to be useful for the treatment of malaria. Read More
3D illustration demonstrating antibody-drug conjugate.

Antibody-drug conjugate specifically delivering a STING agonist to tumors improves immunotherapy

Several STING agonists have demonstrated antitumor efficacy in preclinical studies and are currently under clinical development. However, systemic administration of STING agonists may have adverse effects, while intratumoral injection is limited by tumor accessibility. Therefore, systemic delivery of STING agonists specifically targeted to tumors emerges as a potential strategy to overcome these limitations. Read More

Novartis divulges new WRN inhibitors

Novartis AG has identified triazolo-pyrimidine analogues acting as Werner syndrome ATP-dependent helicase (WRN) inhibitors reported to be useful for the treatment of cancer. Read More

Alkermes Controlled Therapeutics discovers new orexin OX2 receptor agonists

Alkermes Controlled Therapeutics Inc. has patented orexin OX2 receptor (OX2R) agonists reported to be useful for the treatment of cataplexy. Read More
Photomicrograph of hepatocellular carcinoma

EWSAT1 as novel prognosis marker and therapeutic target for hepatocellular carcinoma

Researchers from Fudan University presented data from a study that aimed to assess the significance of a newly found long noncoding RNA (lncRNA), Ewing sarcoma-associated transcript 1 (EWSAT1), in hepatocellular carcinoma (HCC) metastasis. Read More

Other news to note for Dec. 16, 2022

Additional early-stage research and drug discovery news in brief, from: Tiziana Life Sciences, XNK Therapeutics. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe